A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18actual
Sites
21
Countries
Austria, Belgium, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The decision to close the study was made due to the expiration of remaining drug supply.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-10 | actual | When the study began enrolling |
| Primary completion | 2026-05-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-11 | actual | The whole study's end, after follow-up |
| First posted | 2020-11-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Myelofibrosis
- Postlung Transplant (Bronchiolitis Obliterans)
- Chronic Graft Versus Host Disease
Intervention
- Drug: itacitinib — also filed as INCB039110
Primary outcome
what the primary-completion date above is the date OFTreatment Emergent Adverse Events (TEAE's)
measured 3 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed